A systematic review of 12 real-world studies found that difelikefalin, a kappa-opioid agonist approved for chronic kidney disease-associated pruritus, reduced itching in 35-93% of hemodialysis patients, though with wider effectiveness ranges than clinical trials. Common side effects included dizziness, diarrhea, and altered mental status, with no treatment-related deaths reported.
Chronic kidney disease-associated pruritus (CKD-aP) affects more than half of hemodialysis patients and meaningfully worsens quality of life and treatment adherence. The condition has historically been difficult to manage. Difelikefalin, a selective kappa-opioid receptor agonist, received regulatory approval based on the KALM-1 and KALM-2 clinical trials, but how well these trial results translate to everyday clinical practice has remained uncertain. A new systematic review synthesized real-world evidence to answer this question.
The review identified 12 studies across real-world clinical settings involving 3,524 patients with CKD-aP using difelikefalin. The key finding: effectiveness in routine practice was more variable than in controlled trials. In the original KALM-1 and KALM-2 trials, 51% of patients achieved a clinically meaningful reduction (3 or more points) on the Worst Itch-Numeric Rating Scale (WI-NRS). In real-world settings, this ranged from 35% to 92.9% depending on the study population and clinical context. This substantial range suggests that patient selection, dosing practices, or adherence patterns differ meaningfully between trial conditions and routine care.
Sleep quality showed the most consistent benefit across real-world studies. All studies that measured sleep-related quality of life outcomes reported statistically significant improvements, despite variation in overall itching reduction. This suggests difelikefalin may have particular value for patients where pruritus is severely disrupting sleep. Quality of life assessments using the Skindex-10 tool also demonstrated benefit in the studies that measured it, pointing to broader impacts beyond itch intensity alone.
The safety profile identified in real-world use was more complex than the efficacy data. Adverse event incidence ranged from 0% to 64.4% across studies, with 6.3-16% of events classified as treatment-related. The most commonly reported adverse effects were dizziness, diarrhea, nausea, hyperkalaemia (elevated potassium), somnolence, and altered mental status. The altered mental status finding is noteworthy given that opioid receptor agonists can affect cognition. However, the review found no treatment-related deaths or fatal serious adverse events attributed to difelikefalin across all included studies. This suggests a safety floor exists in real-world use, though neurological and gastrointestinal side effects warrant careful monitoring.
If you have kidney disease-related itching, this review suggests difelikefalin is a treatment option with demonstrated real-world effectiveness, though results will vary. The stronger consistency of sleep improvement means if your itching primarily disrupts sleep, this drug may be more likely to help than for other itch patterns. Work with your nephrologist to discuss whether your specific itch profile and broader clinical picture align with the populations studied.
The broader effectiveness range in real-world settings compared to trials indicates that individual response is more variable than initial approval data suggested. Starting with realistic expectations about response rates (35-93% achieved meaningful improvement) rather than assuming the 51% trial figure is prudent. If you experience dizziness, altered mental status, or gastrointestinal effects, these are recognized risks that warrant communication with your care team rather than automatic discontinuation.
The review also highlights a significant gap: most evidence comes from hemodialysis patients, with limited data on difelikefalin for peritoneal dialysis or earlier-stage kidney disease. If you fall into these categories, ask your provider whether any institution-specific or emerging data exists for your population, as generalization from hemodialysis cohorts may not fully apply.
| Attribute | Detail |
|---|---|
| Study type | Systematic review of real-world evidence |
| Studies included | 12 observational and trial extension studies |
| Total participants | 3,524 patients with CKD-aP |
| Primary outcomes | WI-NRS reduction, 5-D Itch scores, Skindex-10 quality of life, safety |
| Key finding: effectiveness | 35-92.9% achieved ≥3-point WI-NRS reduction (vs. 51% in KALM trials) |
| Key finding: sleep | 100% of studies measuring sleep showed significant benefit |
| Key finding: safety | 6.3-16% treatment-related adverse events; no fatal events |
| Common adverse effects | Dizziness, diarrhea, nausea, hyperkalaemia, somnolence, altered mental status |
| Registration | Prospectively registered as CRD420251266218 |
| Journal | Renal Failure |
| Publication ID | PubMed |
Difelikefalin real-world effectiveness and safety systematic review on PubMed
ProtocolEngine provides general health information based on published research. This is not medical advice. Consult a healthcare professional before starting any supplement or health protocol.